Excessive mucin production are the common mechanism and characteristics of chronic obstructive pulmonary disease (COPD) and bronchial asthma. We demonstrate that Peroxiredoxin 6 (Prdx6) plays important roles in the development of mucin overproduction after LPS exposure. Treatment with Prdx6 may provide a new therapy against airway inflammation in the future.